LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Stock List・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Closed

SectorHealthcare

17.31 -4.05

Buy Sell

Overview

Share price change

24h

Current

Min

17.08

Max

17.41

Key metrics
By Trading Economics
Income	25M -43M
Sales	-3.6M 65M
EPS	-0.48
Profit margin	-65.788
Employees	298
EBITDA	-16M -31M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+123.01% upside

Dividends
By Dow Jones
Next Earnings	3 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-182M 1.7B
Previous open	21.36
Previous close	17.31

News Sentiment

By Acuity

100%

319 / 344 Healthcare

Syndax Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2026, 19:20 UTC

Major Market Movers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7 Jun 2026, 23:46 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7 Jun 2026, 23:36 UTC

Market Talk

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7 Jun 2026, 18:00 UTC

Earnings

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6 Jun 2026, 12:40 UTC

Acquisitions, Mergers, Takeovers

Correction to Texas Billionaires Article America's Resort -- WSJ

6 Jun 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6 Jun 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6 Jun 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 Jun 2026, 00:14 UTC

Acquisitions, Mergers, Takeovers

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 Jun 2026, 21:27 UTC

Earnings

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 Jun 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 Jun 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 Jun 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 Jun 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 Jun 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 Jun 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 Jun 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 Jun 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 Jun 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 Jun 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 Jun 2026, 18:33 UTC

Acquisitions, Mergers, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 Jun 2026, 17:50 UTC

Earnings

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 Jun 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 Jun 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 Jun 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 Jun 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 Jun 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 Jun 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer Comparison

Price change

Syndax Pharmaceuticals Inc Forecast

Price Target

By TipRanks

123.01% upside

12 Months Forecast

Average 38.67 USD 123.01%

High 46 USD

Low 29 USD

Based on 10 Wall Street analysts offering 12 month price targets forSyndax Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Syndax Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

319 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.